Your browser doesn't support javascript.
loading
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
Shivapurkar, Narayan; Gay, Martha D; He, Aiwu Ruth; Chen, Wenqiang; Golnazar, Shermineh; Cao, Hong; Duka, Tetyana; Kallakury, Bhaskar; Vasudevan, Sona; Smith, Jill P.
  • Shivapurkar N; Department of Medicine, Georgetown University, Washington, DC 20007, USA.
  • Gay MD; Department of Medicine, Georgetown University, Washington, DC 20007, USA.
  • He AR; Department of Oncology, Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA.
  • Chen W; Department of Medicine, Georgetown University, Washington, DC 20007, USA.
  • Golnazar S; Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC 20057, USA.
  • Cao H; Department of Medicine, Georgetown University, Washington, DC 20007, USA.
  • Duka T; Department of Medicine, Georgetown University, Washington, DC 20007, USA.
  • Kallakury B; Department of Pathology, MedStar Georgetown University Hospital, Washington, DC 20007, USA.
  • Vasudevan S; Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC 20057, USA.
  • Smith JP; Department of Medicine, Georgetown University, Washington, DC 20007, USA.
Int J Mol Sci ; 24(4)2023 Feb 11.
Article en En | MEDLINE | ID: mdl-36835036

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proglumida / Receptores de Colecistoquinina / Carcinoma Hepatocelular / Inhibidores de Puntos de Control Inmunológico / Neoplasias Hepáticas Límite: Animals Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proglumida / Receptores de Colecistoquinina / Carcinoma Hepatocelular / Inhibidores de Puntos de Control Inmunológico / Neoplasias Hepáticas Límite: Animals Idioma: En Año: 2023 Tipo del documento: Article